Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial

Fig. 1

(A) Montgomery-Asberg Depression Rating Scale (MADRS) scores of the patients included in the study. B Mean difference in Montgomery-Asberg Depression Rating Scale (MADRS) scores over ten weeks of open treatment with Maraviroc versus eight weeks of follow-up. C 16-item quick inventory of depressive symptoms- self-report (QIDS-SR16) scores of the patients included in the study. D Clinical global impression (CGI) scores of the patients included in the study. E GAD-7 scores of the patients included in the study

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us